Boris Hadaschik discusses the final overall survival analysis of the phase 3 placebo-controlled SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (6:00).
29-05-2020 | ASCO 2020 | Conference coverage | Video
29-05-2020 | ASCO 2020 | Conference coverage | Video
Boris Hadaschik discusses the final overall survival analysis of the phase 3 placebo-controlled SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (6:00).